FDA's Overreach on Compounded Peptides The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide FDA considers adding a dozen peptides to its bulk drug compounding list RAPS FDA Peptide Update: Category 2 Removals Explained